Your browser doesn't support javascript.
loading
The role of xerostomia in burning mouth syndrome: a case-control study / O papel da xerostomia na sindrome da ardencia bucal: estudo caso controle
Silva, Luciana Alvarenga da; Siqueira, Jose Tadeu Tesseroli de; Teixeira, Manoel Jacobsen; Siqueira, Silvia Regina Dowgan Tesseroli de.
  • Silva, Luciana Alvarenga da; Universidade de Sao Paulo. Departmento de Neurologia. Sao Paulo. BR
  • Siqueira, Jose Tadeu Tesseroli de; Universidade de Sao Paulo. Departmento de Neurologia. Sao Paulo. BR
  • Teixeira, Manoel Jacobsen; Universidade de Sao Paulo. Departmento de Neurologia. Sao Paulo. BR
  • Siqueira, Silvia Regina Dowgan Tesseroli de; Universidade de Sao Paulo. Departmento de Neurologia. Sao Paulo. BR
Arq. neuropsiquiatr ; 72(2): 91-98, 02/2014. tab, graf
Article in English | LILACS | ID: lil-702554
ABSTRACT

Objective:

To assess the efficacy of anti-xerostomic topical medication (urea 10%) in patients with burning mouth syndrome (BMS).

Method:

Thirty-eight subjects diagnosed with BMS according to the International Association for the Study of Pain guidelines were randomized to either placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water qsp 100 g) or treatment (urea 10%) to be applied to the oral cavity 3-4 times per day for 3 months. The patients were evaluated before and after treatment with the following instruments the EDOF-HC protocol (Orofacial Pain Clinic – Hospital das Clínicas), a xerostomia questionnaire, and quantitative sensory testing.

Results:

There were no differences in salivary flow or gustative, olfactory, or sensory thresholds (P>0.05). Fifteen (60%) patients reported improvement with the treatments (P=0.336).

Conclusion:

In conclusion, there were no differences between groups, and both exhibited an association between reported improvement and salivation. .
RESUMO

Objetivo:

Avaliar a eficácia do uso de medicação tópica anti xerostomica (ureia 10%) em pacientes com síndrome de ardência bucal.

Método:

Trinta e oito sujeitos diagnosticados com síndrome de ardência bucal de acordo com os critérios da Associação Internacional para Estudo da Dor foram randomizados para grupo placebo (5% de carboximetilcelulose de sódio, 0,15% de metilparabeno e 10% de glicerol em água destilada qsp 100g) ou grupo tratamento (ureia 10%) para ser aplicada na cavidade oral 3-4 vezes ao dia, durante três meses. Os pacientes foram avaliados antes e depois do tratamento protocolo EDOF-HC, questionário de xerostomia, testes sensitivos quantitativos.

Resultados:

Não houve diferenças no fluxo salivar, limiares gustativos, olfativos e somestésicos (Mann-Whitney P>0,05). Quinze (60%) dos pacientes tiveram melhora com o tratamento (P=0,336, oneway ANOVA ).

Conclusão:

Em conclusão não houve diferenças entre os grupos, ambos apresentaram uma associação entre melhora e salivação. .
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Urea / Xerostomia / Burning Mouth Syndrome / Analgesics, Non-Narcotic / Amitriptyline Type of study: Controlled clinical trial / Practice guideline / Observational study / Qualitative research / Risk factors Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2014 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Universidade de Sao Paulo/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Urea / Xerostomia / Burning Mouth Syndrome / Analgesics, Non-Narcotic / Amitriptyline Type of study: Controlled clinical trial / Practice guideline / Observational study / Qualitative research / Risk factors Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2014 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Universidade de Sao Paulo/BR